Claims
- 1. A therapeutic composition for treating a human or animal comprising,
a compound capable of altering nucleic acid function admixed with a block copolymer, wherein the block copolymer has the following formula: 13wherein: the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is between about 5000 and about 7000 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes between about 10% to about 40% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes between about 60% and about 90% of the compound by weight.
- 2. The composition of claim 1, wherein:
the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is about 6750 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes about 10% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes about 90% of the compound by weight.
- 3. The composition of claim 1, wherein:
the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is about 5750 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes approximately 10% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes about 90% of the compound by weight.
- 4. The composition of claim 1, wherein:
the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is about 5220 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes about 10% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes about 90% of the compound by weight.
- 5. The composition of claim 1, wherein the compound capable of altering nucleic acid sequence function is selected from genes, oligonucleotides, antisense oligonucleotides, triplex DNA compounds, or ribozymes.
- 6. The composition of claim 1, further comprising approximately 0.1% to approximately 5% by weight of a surfactant and approximately 0.5% to approximately 5% by volume of an low molecular weight alcohol.
- 7. The composition of claim 6, wherein the surfactant is Tween 80 and the alcohol is ethanol.
- 8. The composition of claim 1, further comprising an expression vector, wherein the compound capable of altering nucleic acid sequence function is a nucleic acid sequence contained in the expression vector, and the expression vector is capable of expressing the nucleic acid sequence.
- 9. A therapeutic composition for treating a human or animal comprising,
a compound capable of altering nucleic acid function admixed with a block copolymer, wherein the block copolymer has the following formula: 14wherein: the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is between about 5000 and about 7000 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes between about 10% to about 40% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes between about 60% and about 90% of the compound by weight.
- 10. The composition of claim 9, wherein:
the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is about 6750 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes about 10% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes about 90% of the compound by weight.
- 11. The composition of claim 9, wherein:
the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is about 5750 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes approximately 10% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes about 90% of the compound by weight.
- 12. The composition of claim 9, wherein:
the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is about 5220 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes about 10% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes about 90% of the compound by weight.
- 13. The composition of claim 9, wherein the compound capable of altering nucleic acid sequence function is selected from genes, oligonucleotides, antisense oligonucleotides, triplex DNA compounds, or ribozymes.
- 14. The composition of claim 9, further comprising approximately 0.1% to approximately 5% by weight of a surfactant and approximately 0.5% to approximately 5% by volume of an low molecular weight alcohol.
- 15. The composition of claim 14, wherein the surfactant is Tween 80 and the alcohol is ethanol.
- 16. The composition of claim 9, further comprising an expression vector, wherein the compound capable of altering nucleic acid sequence function is a nucleic acid sequence contained in the expression vector, and the expression vector is capable of expressing the nucleic acid sequence.
- 17. A therapeutic composition for treating a human or animal comprising,
a compound capable of altering nucleic acid function admixed with a block copolymer, wherein the block copolymer has the following formula: 15wherein: the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is between about 5000 and about 7000 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes between about 5% to about 20% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes between about 80% and about 95% of the compound by weight.
- 18. The composition of claim 17, wherein:
the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is about 6750 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes about 10% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes about 90% of the compound by weight.
- 19. A method of delivering a compound capable of altering nucleic acid sequence function to a human or animal comprising,
the step of administering to a human or animal a composition comprising a compound capable of altering nucleic acid sequence function admixed with a block copolymer, wherein the block copolymer has the following formula: 16wherein: the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is between about 5000 and about 7000 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes between about 10% to about 40% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes between about 60% and about 90% of the compound by weight.
- 20. The composition of claim 19, wherein:
the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is about 6750 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes about 10% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes about 90% of the compound by weight.
- 21. The composition of claim 19, wherein:
the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is about 5750 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes approximately 10% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes about 90% of the compound by weight.
- 22. The composition of claim 19, wherein:
the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is about 5220 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes about 10% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes about 90% of the compound by weight.
- 23. The method of claim 19, wherein the compound capable of altering nucleic acid sequence function is selected from genes, oligonucleotides, antisense oligonucleotides, triplex DNA compounds, or ribozymes.
- 24. The method of claim 19, further comprising approximately 0.1% to approximately 5% by weight of a surfactant and approximately 0.5% to approximately 5% by volume of an low molecular weight alcohol.
- 25. The method of claim 24, wherein the surfactant is Tween 80 and the alcohol is ethanol.
- 26. The method of claim 19, further comprising an expression vector, wherein the compound capable of altering nucleic acid sequence function is a nucleic acid sequence contained in the expression vector, and the expression vector is capable of expressing the nucleic acid sequence.
- 27. A method of delivering a compound capable of altering nucleic acid sequence function to a human or animal comprising,
the step of administering to a human or animal a composition comprising a compound capable of altering nucleic acid sequence function admixed with a block copolymer, wherein the block copolymer has the following formula: 17wherein: the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is between about 5000 and about 7000 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes between about 10% to about 40% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes between about 60% and about 90% of the compound by weight.
- 28. The composition of claim 27, wherein:
the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is about 6750 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes about 10% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes about 90% of the compound by weight.
- 29. The composition of claim 27, wherein:
the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is about 5750 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes approximately 10% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes about 90% of the compound by weight.
- 30. The composition of claim 27, wherein:
the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is about 5220 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes about 10% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes about 90% of the compound by weight.
- 31. The method of claim 27, wherein the compound capable of altering nucleic acid sequence function is selected from genes, oligonucleotides, antisense oligonucleotides, triplex DNA compounds, or ribozymes.
- 32. The method of claim 27, further comprising approximately 0.1% to approximately 5% by weight of a surfactant and approximately 0.5% to approximately 5% by volume of an low molecular weight alcohol.
- 33. A method of delivering a compound capable of altering nucleic acid sequence function to a human or animal comprising,
the step of administering to a human or animal a composition comprising a compound capable of altering nucleic acid sequence function admixed with a block copolymer, wherein the block copolymer has the following formula: 18wherein: the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is between about 5000 and about 7000 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes between about 5% to about 20% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes between about 80% and about 95% of the compound by weight.
- 34. The composition of claim 33, wherein:
the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is about 6750 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes about 10% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes about 90% of the compound by weight.
- 35. The composition of claim 33, wherein:
the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is about 5750 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes approximately 10% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes about 90% of the compound by weight.
- 36. The composition of claim 33, wherein:
the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is about 5220 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes about 10% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes about 90% of the compound by weight.
- 33. The method of claim 32, wherein the surfactant is Tween 80 and the alcohol is ethanol.
- 34. The method of claim 27, further comprising an expression vector, wherein the compound capable of altering nucleic acid sequence function is a nucleic acid sequence contained in the expression vector, and the expression vector is capable of expressing the nucleic acid sequence.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of co-pending U.S. application Ser. No. 09/457,771, filed Dec. 9, 1999, which is a continuation of U.S. application Ser. No. 09/104,088, filed Jun. 24, 1998, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 08/926,297, filed Sep. 5, 1997, now abandoned, which is a continuation of U.S. application Ser. No. 08/725,842, filed Sep. 30, 1996, now abandoned, which is a continuation of U.S. application Ser. No. 08/138,271, filed Oct. 15, 1993, now abandoned.
[0002] This application also claims priority under 35 U.S.C. § 120 to co-pending U.S. application Ser. No. 09/368,855, filed Aug. 5, 1999, which is a continuation of U.S. application Ser. No. 08/889,342 filed Jul. 8, 1997, now U.S. Pat. No. 5,990,241, which is a continuation of U.S. application Ser. No. 08/657,161, filed Jun. 3, 1996, now U.S. Pat. No. 5,691,387, which is a division of U.S. application Ser. No. 08/087,136 filed Jul. 2, 1993, now U.S. Pat. No. Re. 36,665, which is a continuation of U.S. application Ser. No. 07/847,874 filed Mar. 13, 1992, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 07/673,289, filed Mar. 19, 1991, now abandoned.
Divisions (1)
|
Number |
Date |
Country |
Parent |
08087136 |
Jul 1993 |
US |
Child |
08657161 |
Jun 1996 |
US |
Continuations (5)
|
Number |
Date |
Country |
Parent |
09104088 |
Jun 1998 |
US |
Child |
09368855 |
Aug 1999 |
US |
Parent |
08725842 |
Sep 1996 |
US |
Child |
08926297 |
Sep 1997 |
US |
Parent |
08138271 |
Oct 1993 |
US |
Child |
08725842 |
Sep 1996 |
US |
Parent |
08657161 |
Jun 1996 |
US |
Child |
08889342 |
Jul 1997 |
US |
Parent |
07847874 |
Mar 1992 |
US |
Child |
08087136 |
Jul 1993 |
US |
Continuation in Parts (4)
|
Number |
Date |
Country |
Parent |
09457771 |
Dec 1999 |
US |
Child |
09919504 |
Jul 2001 |
US |
Parent |
09368855 |
Aug 1999 |
US |
Child |
09919504 |
Jul 2001 |
US |
Parent |
08926297 |
Sep 1997 |
US |
Child |
09104088 |
Jun 1998 |
US |
Parent |
07673289 |
Mar 1991 |
US |
Child |
07847874 |
Mar 1992 |
US |